Inhibition of Transcription of the Human c-<i>myc </i>Protooncogene by Intermolecular Triplex
Hyung‐Gyoon Kim(University of Alabama at Birmingham), Donald M. Miller(University of Louisville), James F. Reddoch(University of Alabama at Birmingham), S.R. Thomas(University of Alabama at Birmingham), David E. Jones(University of Alabama at Birmingham), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nadarajah Vigneswaran(University of Alabama at Birmingham), Charles A. Mayfield(Baylor College of Medicine)
Cited by 48
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k